ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Akero Therapeutics Inc.

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

November 07, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

October 09, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025

October 07, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 28, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

August 14, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 08, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 03, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

May 10, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

May 09, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

May 09, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

May 07, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

April 30, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 28, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 30, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

January 28, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Announces Proposed Public Offering of Common Stock

January 27, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

January 27, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

January 24, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

January 13, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 07, 2025

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

November 26, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

November 15, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

November 13, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 08, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

October 21, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

September 30, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

September 09, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 28, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Tickers AKRO

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.